PepTrackevidence-graded reference
Epitalon (Epithalon)
fig.1 — stylized molecular motif
Longevity

Epitalon (Epithalon)

AEDG · pineal tetrapeptide

Flagship 'telomere/anti-aging' peptide in longevity/biohacking; used in short cycles a few times/year.

Evidence
Emechanistic / anecdotal
Status
Removed from Cat 2 · pending PCACas of 2026-06
Approval
Not approved
Category
Longevity
Route
Subcutaneous · Intramuscular · Sublingual
Demand rank
honorable mention
01Dosing & Protocol
Typical · reference only
5-10 mg/day SC for a 10-20 day cycle, ~2-3x/yr (human trials used 0.5-1 mg/day - 10-20x lower)
Titration
None
Reconstitution — illustrative, not a recommendation
10 mg vial + 2 mL BAC = 5 mg/mL; 5 mg = 100 U (full syringe); 10 mg/day = 200 U (two draws). Many use 10 mg/1 mL for easier dosing.
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. FDA review is insomnia-scoped; a favorable vote would NOT validate longevity claims. FDA flags immunogenicity.
Status
Removed from Cat 2 · pending PCAC
503A bulks
Not on the bulks list
Category 2
Removed from Category 2 Apr 2026
PCAC review
2026-07-24 (scoped to INSOMNIA, not longevity)
WADA
Not listed
03Evidence — the honest read
What the evidence actually shows

Single-lab (Khavinson) human data + one 2025 independent in-vitro replication (Brunel). Marquee mortality results were EPITHALAMIN (extract), not the synthetic tetrapeptide. 2025 review: human safety/PK 'missing.'

04Safety
Contraindications
  • Active/prior cancer (telomerase activation; precautionary)
  • Pregnancy/breastfeedinghard stop
  • Immune/autoimmune reactivity (FDA immunogenicity flag)
Key interactions
  • Melatonin/sedatives (theoretical additive circadian effect)
Serious signals
  • Cancer plausibility via telomerase (no human carcinogenicity data)
  • 10-20x dose gap vs trials
Monitoring
None validated.
05Related in Longevity
NAD+ (and precursors NMN/NR)
mechanistic / anecdotal
grade E →
06Sources
1IJMS 2025 review; Brunel 2025
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: lean-skeptical
← All peptides
Longevity

Epitalon (Epithalon)

AEDG · pineal tetrapeptide

Flagship 'telomere/anti-aging' peptide in longevity/biohacking; used in short cycles a few times/year.

Evidence
E
mechanistic / anecdotal
Status
Removed from Cat 2 · pending PCAC
as of 2026-06
FDA approval
Not approved
off-label / gray
Route
Subcutaneous · Intramuscular · Sublingual
Community / anecdotal
Demand
—
honorable mention
WADA
Not listed
sport-legal
01

Dosing & protocol

Community / anecdotal. Community / anecdotal — no regulatory basis. Not medical advice.
Typical — reference only

5-10 mg/day SC for a 10-20 day cycle, ~2-3x/yr (human trials used 0.5-1 mg/day - 10-20x lower)

Worked reconstitution example

10 mg vial + 2 mL BAC = 5 mg/mL; 5 mg = 100 U (full syringe); 10 mg/day = 200 U (two draws). Many use 10 mg/1 mL for easier dosing.

Titration

None

Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial (use the calculator →).
02

Regulatory status

Removal from Category 2 ≠ legal to compound ≠ FDA-approved. FDA review is insomnia-scoped; a favorable vote would NOT validate longevity claims. FDA flags immunogenicity.
StatusRemoved from Cat 2 · pending PCAC
503A bulksNot on the bulks list
Category 2 (2026)Removed from Category 2 Apr 2026
PCAC review2026-07-24 (scoped to INSOMNIA, not longevity)
WADANot listed
03

Evidence — the honest read

Emechanistic / anecdotal

Single-lab (Khavinson) human data + one 2025 independent in-vitro replication (Brunel). Marquee mortality results were EPITHALAMIN (extract), not the synthetic tetrapeptide. 2025 review: human safety/PK 'missing.'

04

Safety

Contraindications
  • Active/prior cancer (telomerase activation; precautionary)
  • Pregnancy/breastfeedinghard stop
  • Immune/autoimmune reactivity (FDA immunogenicity flag)
Key interactions
  • Melatonin/sedatives (theoretical additive circadian effect)
Serious signals
  • Cancer plausibility via telomerase (no human carcinogenicity data)
  • 10-20x dose gap vs trials
Monitoring

None validated.

06

Sources

01IJMS 2025 review; Brunel 2025
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: lean-skeptical